The Patent Finder

Biomarin Technologies B.V.

14 patents currently held · Updated Nov 21, 2026
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Prosensa Technologies B.V. (to 2015)

10
Ending by 2030
Jul 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jul 14, 2027
    The maintenance fee for Oligonucleotide comprising an inosine for treating DMD (US 10,533,171) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,519,097Molecules for targeting compounds to various selected organs or tissues
In force
 · USPTO record
In forceUSPTO record
US 9,499,818Methods and Means for Efficient Skipping of at Least One of the Exons 51-53, 55, 57 and 59 of the Human Duchenne Muscular Dystrophy Gene
In force
 · Medium confidence
In forceMedium confidence
US 9,528,109METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA
In force
 · Low confidence
In forceLow confidence
US 9,926,557METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA
In force
 · High confidence
In forceHigh confidence
US 10,876,114Methods and Means for Efficient Skipping of at Least One of the Following Exons of the Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53
In force
 · Medium confidence
In forceMedium confidence
US 11,427,820METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA
In force
 · Medium confidence
In forceMedium confidence
US RE48,468Means and methods for counteracting muscle disorders
In force
 · USPTO record
In forceUSPTO record
US 10,533,171Oligonucleotide comprising an inosine for treating DMD
In force
 · USPTO record
In forceUSPTO record
US 11,034,956Oligonucleotide comprising an inosine for treating DMD
In force
 · USPTO record
In forceUSPTO record
US 11,634,714Oligonucleotide comprising an inosine for treating DMD
In force
 · USPTO record
In forceUSPTO record
10 of 14 patents shown.
Pro members see all 14.
Pro members: see all 14 patents
Also on record, not counted in the 14: 6 patents in force now held by others · 5 lapsed for an unpaid fee · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 9 abandoned · 6 no status recorded

Rows 11 to 19 of 19 are for members. The first 10 are on the company page.
Pro members see all 19 published applications.
Upgrade to Pro
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited